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A Randomized Trial of Nebulized 3% Hypertonic Saline
With Salbutamol in the Treatment of Acute Bronchiolitis in
Hospitalized Infants
Pedro Flores, MD, PhD,* Ana Luisa Mendes, MD, and Ana S. Neto, MD, PhD
Summary. Objective: Acute bronchiolitis is a common disorder of infants that often results in
hospitalization. Apart from supportive care, no therapy has been shown to influence the course of the
disease,except forapossibleeffectofnebulizedhypertonicsaline (HS).Todeterminewhether thisdoes
have beneficial effects on length of stay in hospital or on severity scores, we undertook a double-blind,
randomized, controlled trial in a pediatric department of a Portuguese hospital. Methods: Previously
healthy infants, younger than 12 months, hospitalized with mild-to-moderate acute viral bronchiolitis
were randomized to receive either nebulized 3% (hypertonic, HS) or 0.9% (normal, NS) saline during
their entirehospital stay.Primaryendpointswere: lengthof hospital stayandseverity scoresoneachday
of hospitalization. Need for supplemental oxygen, further add-onmedications and adverse effectswere
alsoanalyzed.Results: Sixty-eight patients completed the study (HS: 33;NS: 35). Themedian length of
hospital stay did not differ between groups: HS: 5.62.3 days; NS: 5.42.1 days (P¼0.747). We
foundnodifferencebetweengroups in severity scores fromday1 to day4. Therewerenodifferences in
need for supplemental oxygen or add-on medications. Patients in HS group had significantly more
cough (46%vs. 20%,P¼0.025) and rhinorrhoe (58%vs. 31%,P¼0.30). Conclusion: This study does
not support the use of nebulized HS over NS in therapy of hospitalized children with mild-to-moderate
acute viral bronchiolitis. Pediatr Pulmonol.  2015 Wiley Periodicals, Inc.
Key words: Pneumonia; TB; viral; evidence-based medicine & outcomes; asthma & early
wheeze.
INTRODUCTION
Acute bronchiolitis is an infection of the lower
respiratory tract, typical of infants, most commonly
caused by respiratory syncytial virus (RSV).1 It is the
leading cause of hospitalization for respiratory disease in
infants, with an estimated 80,000 cases and 10,000
hospital days in Portugal each year, constituting a
significant burden in health expenditure.2–9
Since wheeze is sometimes a feature of bronchiolitis,
asthma treatments are frequently used. Nevertheless,
pathophysiology of bronchiolitis is quite different: it
affects the bronchiolar epithelium, with necrosis and
sloughing of epithelial cells, edema, increased secretion
of mucus, and peribronchiolar cell infiltration. These
changes obstruct large and small airways, leading to
wheezing, atelectasis, and hyperinflation.9,10
Beta-agonists, corticosteroids, and diuretics are gener-
ally considered ineffective for bronchiolitis. In spite of
some therapeutic benefit of nebulized epinephrine, the
mainstay of treatment of acute bronchiolitis remains
hydration, supplemental oxygen, and tube feeding, when
necessary.1,9–11
Inhaled hypertonic saline (HS) has recently been
shown to be a promising therapy, because of its ability to
draw fluid from the submucosa and adventitial spaces,
decreasing airway edema.10–13 In cystic fibrosis and
bronchiectasis, studies have found significant improve-
ment of broncho-pulmonary and rhino-sinusal mucous
rheologic properties, which could be relevant in infants
with acute bronchiolitis.11–14 Immunomodulator effects
of HS have also been suggested.15,16
It has been demonstrated that nebulized HS is
associated with decreasing hospital admissions,2,16,17 its
length,14,18–21 and severity scores,15,18,20,21 in patients
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with acute viral bronchiolitis. A recent Cochrane
metanalysis recommends use of nebulized HS in these
patients.10
The objective of this study was to compare the efficacy
of inhaled HS vs normal saline (NS), on length of stay and
severity scores in infants with acute viral bronchiolitis.
Secondary outcomes were: need for supplemental
oxygen, tube feeding, and add-on therapies. Safety of
HS was also evaluated.
PATIENTS AND METHODS
Settings
We conducted a randomized, double-blind controlled
trial in a pediatric department of a general urban hospital
(Hospital CUF Descobertas—Lisbon, Portugal), compar-
ing 3% hypertonic saline (HS group) with 0.9% normal
saline (NS group). Patients were evaluated in the
Emergency Department (ED) and admitted to the
Pediatric Ward of the same Hospital. The study was
conducted during two winter seasons (2012–2013 and
2013–2014, from November 1st to April 30th).
Patients
We included 68 infants, admitted with the diagnosis of
acute viral bronchiolitis, defined as an apparent viral
respiratory tract infection diagnosed in an infant with
nasal discharge and wheezy cough, in the presence of fine
inspiratory crackles and/or high pitched expiratory
wheeze, in which apnoe could be a presenting feature.22,23
Inclusion criterion was: infants aged less than 12-months
with acute bronchiolitis. Exclusion criteria were: previous
episodes of wheezing; personal history of prematurity
(gestational age <34 weeks); physician diagnosis of
eczema, food allergy, or chronic (cardiac, respiratory,
immunological, neurological, or metabolic) disease; high
severity criteria (coma, respiratory rate>80 breaths/minute,
oxygen saturation <88% on room air or need for assisted
ventilation).
Study Design
Physicians working in the ED performed a standard
history and physical examination on all patients and
assessed them for study eligibility.
Patients were randomized by the Hospital Pharmacy
before inclusion, using a computer random number
generator (Excel for WindowsTM v. 2013). The randomi-
zation list was concealed by the Pharmacy until
completion of the study. Physicians, nurses, study
personnel and patients’ families remained blinded to
treatment allocation throughout the trial.
The same staff prepared the study solutions as
described: 3% hypertonic saline resulted of mixing, in
sterile environment, 11ml of 20% NaCl with 89ml of
0.9% NaCl. The homogenized mixture was divided in
3ml aliquots, that were preserved in the ED refrigerator
between 2 and 88C. They would be usable for a period of
7 days. Commercial preparation of normal saline (0.9%)
were similarly homogenized, divided, and preserved in
the same refrigerator. Both solutions were similar in
appearance and smell, stored in identical syringes, and
labelled only by a code number. Procedures followed
national legislation and hospital good practices. Pharma-
cy is certified by national quality board but has no formal
certificate for preparation of trial medications.
To each 3ml aliquot, nurses added 0.25ml (1.25mg) of
salbutamol. The mixture was given to the patient by
nebulization.19,24 When salbutamol solution was added,
actual concentration of NaCl lowered from 3% to 2.77%
in HS and from 0.9% to 0.83% in NS.
Infants received the same code treatment every 6 h until
discharge. After deep nasal suctioning, it was delivered
through a tight fixing face mask (Pediatric EcoliteTM
Aerosol Mask, Wokingham, Berkshire, United King-
dom), from a standard oxygen-driven nebulizer (Cirrus 2
NebuliserTM, Wokingham, Berkshire, United Kingdom),
connected to a source of pressurized oxygen from the
wall, set to a flow rate of 6 L/min, until empty. Mass
median aerodynamic diameter (MMAD) of nebulized
particles was 3.9mm.
All patientswere enrolledwithin 24 hr of admission.Data
on age, sex, gestational age, family history of atopic disease
(eczema, rhinitis, or asthma in mother, father, or sibling),
tobacco smoke exposure (if cohabitants regularly smoked
during pregnancy or after birth), and breastfeeding (current
or exclusive until 3 months) was recorded. Medication
received before trial enrolment was also registered,
including normal saline. At ED, all patients received a trial
of nebulized salbutamol, according to hospital guidelines.
Infants with favorable response were not excluded.
Patients were clinically evaluated at study inclusion and
every day (less than 60min after a scheduled morning
nebulization) until discharge, by the same investigator (PF
or ALM). The following parameters were recorded, using
the clinical score proposed by Wang25: respiratory rate,
wheezing, retraction and general condition. This scoring
system assigns a number of 0–3 to each variable with
increased severity receiving a higher score—maximum of
12 (Table 1).
Three times a day, the hospital personnel on duty
registered the following data in a standardized sheet:
general condition, respiratory rate, presence of wheezing,
costal retractions, oxygen saturation, need for supple-
mental oxygen or tube feeding. Twice a week, the
investigators scheduled meetings with the medical staff,
in order to uniformize criteria between observers, namely
for administration of add-on medications.
Additional inhalations of 1.25mg salbutamol diluted in
NaCl 0.9%or non-diluted 1ml 1:1000 epinephrine or other
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medications (antibiotics, corticosteroids, or diuretics)were
given as needed, according to hospital guidelines.
Hemoglobin oxygen saturation was determined by
Nellcore OximaxTM N-560 with OxiprobeTM BM-201
disposable sensor, Tyco Health Care, United Kingdom.
Each child had nasal secretions collected for Respira-
tory Syncytial Virus (RSV) antigen detection, using a
commercial immunochromatographic assay (RSV Respi-
StripTM, Coris Bioconcept, Gemloux, Belgium). The
sensitivity of the test is 80–90%.
Decisions to request additional tests, provide intrave-
nous fluids, supplemental oxygen or tube feeding were
taken by attending physicians, based on clinical grounds
and hospital guidelines. Supplemental oxygen was started
in infants with a room air saturation of 93% or lower, and
stopped when higher than 93% for 8 hr including a period
of sleep. Tube feeding was initiated when infants could
not get at least 75% of their usual intake by mouth and
stopped when the reverse was true. IV fluids were given to
compensate for fluid loss in clinically dehydrated infants,
or those with vomit or diarrhoe.
Symptoms previously described as adverse effects of HS
were also recorded11,18,26: sudden bronchial constriction,
apnoe, cyanosis, exacerbation of cough, rhinorrhoe, satura-
tion dips, tachycardia >200 cpm, agitation, and vomiting.
Patients were excluded from the study in cases of
clinical deterioration requiring intensive care (at least non-
invasive ventilation) or if parents withhold their consent.
Infants were considered “fit for discharge” when they
did not need supplemental oxygen for 8 hr including a
period of sleep, hadminimal or no chest retraction, and fed
adequately at least 75% of their usual intake with no need
for tube feeding or intravenous fluids. Time of “actual
discharge” was also recorded. The latter was influenced by
social or administrative factors. Wang score at discharge
was recorded but a minimum value was not mandatory.
Measurement of Treatment Effect
We compared the two groups (HS vs. NS), considering
two major outcomes:
a) Length of hospitalization, in days (“Fit to discharge”
and “Actual discharge”).
b) Severity scores on day 1, 2, and 3.
Minor outcomes were:
a) Need for supplemental oxygen and tube feeding and
their duration.
b) Other treatments (further doses of salbutamol, nebu-
lized epinephrine, systemic corticosteroids, antibiot-
ics, or diuretics).
c) Symptoms attributable to side effects of trial solutions.
Ethics
The study was approved by the Hospital’s Ethics
Committee. Informed written consent was obtained from
a parent of each child, before enrolment.
Statistical Analysis
Sample Size Justification
For the first major outcome (hospitalization days), we
found, in previous (non published) studies conducted in
our hospital, and data from other southern European
countries,2,4,7,15,20,21 a mean value of 5.4 days (standard
deviation of 1.2). We considered as clinically significant a
reduction of 1 day. Assuming a a of 0.05 and a power of
90%, we required a sample size of 31 infants in each
group to be able to detect such a difference.
Previousmeasurements of severity score in infants with
bronchiolitis showed that an expectable mean of 6.0 on 12
points (standard deviation of 1.3). To detect a clinically
significant change of at least one point in the severity
score,14,15,18,20,21 and assuming a a of 0.05 and a power of
90%, a sample size of 33 in each group was necessary.
Data Analysis
A databasewas created using SPSS 21 forWindowsTM.
Following descriptive analyses for the entire sample, HS
and NS groups were compared, using independent
samples t-test for normally distributed continuous data,
Mann–Whitney tests for non-normal continuous varia-
bles, and Fisher or Pearson x2 test, as appropriate, for
categorical data. P value< 0.05 was considered statisti-
cally significant.
TABLE 1—Wang Severity Score (Wang et al. 1992)
Punctuation 0 1 2 3
Respiratory rate (breaths/
min)
<30 31–45 46–60 >60
Costal retractions None Intercostal only Tracheosternal Severe with nasal flaring
Wheezing None Terminal expiration or
only with
stethoscope
Entire expiration or audible
on expiration without
stethoscope
Inspiratory and expiratory without
stethoscope
General condition Normal Irritable, lethargic, poor feeding
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RESULTS
Participants’ Flow and Baseline Data
Ninety-eight patients with mild-to-moderate bronchi-
olitis were enrolled, and 68 completed the whole study
(Fig. 1).
There were no significant differences between groups
(HS vs. NS) in baseline characteristics (Table 2).
Excluded patients (that refused to participate or had
clinical deterioration), had similar baseline characteristics
as included subjects (data not shown).
Prior to enrolment, in ED, all patients had deep nasal
suctioning, received nasal 0.9% saline drops, and a trial
nebulization of salbutamol (1.25mg in 3ml of NS).
Before arriving to hospital, nineteen had received
paracetamol (HS: 9; NS: 10), sixteen nasal phenylephrine
(HS: 6; NS: 10), five inhaled salbutamol (HS: 2; NS: 3),
and two anti-hystaminic syrup (HS: 1; NS: 1).
Outcomes of Therapeutic Effects
Major Outcomes
In Table 3, major outcomes (length of stay and severity
scores from day 1 to day 3), are showed:
Minor Outcomes
In Table 4, the following outcomes are presented: need
for supplemental oxygen, tube feeding, and correspond-
ing durations, and added medications. Use of antibiotics
was justified by concomitant acute otitis media or
radiographic chest infiltrates. No significant differences
were found between groups.
In Table 5, possible adverse effect of trial medication
are enumerated. Except for excessive cough and rhinor-
rhoe that occurred more often in Group I (HS), no
differences were found between groups. No child was
withdrawn from the study because of these symptoms.
DISCUSSION
This prospective double blind controlled trial compar-
ing effects of nebulized 3% hypertonic saline (HS) with
0.9% normal saline (NS) in hospitalized infants with
mild-to-moderate acute bronchiolitis showed no signifi-
cant difference in length of stay in hospital, severity
scores, need for supplemental oxygen, tube feeding, or
add-on medications. In addition to this lack of apparent
benefit of the use of HS, we found increased morbidity
(evidenced by higher incidence of cough and rhinorrhoe),
which argues against the use of HS in the management of
acute bronchiolitis.
From eight previously published studies that analysed
length of stay as a primary outcome, four demonstrated a
benefit in reducing average length of stay in hospital
(1.0–1.6 less days in HS group when compared to NS
group)14,15,20,21 and six did not show such a differ-
ence.11–13,18,19,27 Study populations included children
younger than 24 months in most trials, except three, with
up to 12 months-old patients.14,18,27 We believe that
selecting younger patients would allow us to include
children with acute viral bronchiolitis, although we could
not reliably exclude other causes of infant wheezing, such
as infant asthma. Our effort to exclude patients with
medical diagnosis of eczema and food allergy, in addition
to similar distribution, in both groups, of patients with
family history of atopic disease, and absence of
improvement after salbutamol trial in ED, lowered but
did not eliminate bias associated with inclusion of
patients wheezing by other causes.10–18
Differences in study populations are unlikely to explain
the contradictory results. Our population was comparable
to others in respect to size, age, tobacco smoke exposure,
breastfeeding, clinical severity, and RSV identifica-
tion.1,3,11–21 Time of illness before admission was
2.5 days, similar to that found by Anil,17 but lower than
Fig. 1. Flow of patients through the study.
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other studies (average between 3 and 5
days).11,14,15,18–21,26–30 Local practices of diagnosis and
treatment may have influenced our results.
Generalization of length-of-stay findings between
different trials should be undertaken with caution. In the
United States,13,26 Israel,14,18,27 or the Netherlands,11 for
instance, average length of stay of bronchiolitis patients is
1 to 2 days shorter than in Southern Europe2,4,5,7,10 or East
Asia.15,20 Such disparity may, in part, be attributed to
different clinical guidelines and healthcare systems, as
well as medical efficiency, family, transport, social, or
administrative issues. We did not find differences between
groups in time until patients were “fit for discharge” nor
actual times for discharge. Again, possible bias introduced
by local practices cannot be excluded. These findings need
to be confirmed by a multicenter trial, planned for in the
near future.
We found no difference between HS and NS group,
regarding severity scores. Among six previous studies
addressing this topic, conclusions were conflicting:
four studies demonstrated a slight benefit of score in
HS group,15,19–21 with an average reduction of 1.15
points on day 1, 1.32 on day 2 and 1.32 on day 3; two
studies showed no difference in any considered day of
treatment.11,14 In our study, both groups had similar
severity scores. A difference of 0.9 points, in day 2, did
not reach statistical significance. We used Wang
scoring system as we considered it the best available
validated classification and would allow comparison
with other authors.10–21,25 We question, however, the
clinical significance of a one-point drop of severity,
found by other authors.10,15,18,20 Better instruments to
measure clinical outcomes of acute bronchiolitis are
needed. Jacobs, in a recent study, used a different
scoring system, including oxygen saturation and
consolability, allowing a more detailed stratification
of patients.26
Comparing to admission, we found a higher severity
scores on day 1 and 2. Patients were admitted on average
during the third day of illness, earlier than referred by
others.11,14,15,18–21,26,28–30 Concerning the natural history
of bronchiolitis and the absence of specific therapies, we
believe that that readiness could, at least, explain clinical
worsening of patients during hospitalization, with higher
Wang scores and need for supplemental oxygen or tube
feeding.2,4,5,7,22,23
TABLE 2—Patient Demographic Characteristics and Illness Status at Baseline (HS vs. NS)
Characteristic
Hypertonic saline
Group I (HS)
N¼ 33
Normal saline
Group II (NS)
N¼ 35 P value
Mean ( SD) age, months 3.3 2.4 3.8 2.5 0.303
Male N (%) 18 (54.5) 18 (51.4) 0.797
Days of illness before hospitalization (mean SD) 2.3 1.0 2.4 1.0 0.677
Mean ( SD) severity score on admission 5.7 1.9 6.1 1.6 0.306
Family history of atopy N (%) 10 (30.3) 12 (34.3) 0.726
Tobacco smoke exposure N (%) 7 (21.2) 6 (17.1) 0.670
Breastfeeding N (%) 20 (60.6) 18 (51.4) 0.446
RSV N (%) 29 (87.9) 29 (82.9) 0.559
Positive response to salbutamol trial (N) 0 0
Supplemental oxygen at study entry N (%) 16 (48.5) 21 (60.0) 0.465
Tube feeding at study entry N (%) 9 (27.3) 8 (22.9) 0.782
TABLE 3—Major Outcomes for the Two Intervention Groups
Hypertonic saline
Group I (HS)
N¼ 33
Normal saline
Group II (NS)
N¼ 35 P value
Days until “fit to discharge” (mean SD) 4.9 2.4 4.7 2.3 0.621
Days until discharge (mean SD) 5.6  2.3 5.4  2.1 0.747
Severity score D1 (33, 35)1 5.8  2.1 6.3  1.7 0.286
Severity score D2 (33,34)1 5.9  2.3 6.8  2.4 0.099
Severity score D3 (29,31)1 5.5  3.2 5.6  2.7 0.865
Severity score when “fit to discharge” (33,35)1 1.3  1.4 1.5  1.3 0.575
1(N Group I, N Group II).
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Our nebulizers and oxygen flow was similar to
others.3,10,11,14,17,18,26,28–30 Several non-controlled fac-
tors (tidal volumes, crying, cough, combativeness, or
sleepiness) influence deposition of particles in lower
airways. These would justify further assessment. Fre-
quency of inhaled medication in our study should not
justify differences as it was similar to others, which have
used 4,28 6,12,21 or 8 hr intervals.11,13–16,18,20,21
Difference between concentration of NaCl in HS
(2.77%) and NS (0.83%) given three times a day, was low
and could contribute for the lack of effect found in our
study. Studies with different concentrations (5%, 6%, or
7% HS) and frequency of nebulizations, leading to higher
total dosis of sodium chloride have been conducted, with
conflicting results.11,26,29 Normal saline may not be
merely a placebo, as discussed by other authors.11–13,26
The fact that acute bronchiolitis tends to remit spontane-
ously, regardless of treatment, makes it important to
optimize measures of effect of medical interventions.
We associated salbutamol to nebulized HS or NS,
aiming to prevent bronchospasm, potentially associated to
hypertonic solutions.10–13,15,20 Others have used different
bronchodilators such as terbutaline16 or epineph-
rine.14,18,21 In order not to reduce concentration of
NaCl, we used lower doses of salbutamol,11,15,20 without
significant differences.
Wedidnot evaluatepatients before andafter nebulization,
and sowe could not find differences in immediate effects of
therapy.Others have done so,mainly in studies conducted in
ED environment, and found immediate relief provided by
HS, obviously an important result.3,10,13,16,17,26
Other minor outcomes were evaluated in our study:
need for supplemental oxygen, tube feeding and add-on
medications. We did not find differences between HS and
NS groups concerning these indirect markers of severity.
A great variability was found, possibly related to age of
patients and airway calibre. Add-onmedication depended
upon physician decisions, and was mostly administered
without formal indication from guidelines. These atti-
tudes may have introduced a non-quantified bias to our
trial,1,6,9,10,22 that was possibly distributed evenly
between HS and NS groups. As a clinical trial team,
we scheduled meetings with hospital pediatricians, in
order to uniformize indications for medications.
TABLE 4—Minor Outcomes for the Two Intervention Groups
Hypertonic saline
Group I (HS)
N¼ 33
Normal saline
Group II (NS)
N¼ 35 P value
Supplemental oxygen
Patients N (%) 26 (78.8) 32 (91.4) 0.181
Duration (hours)1 91 39 86 40 0.640
Need for tube feeding
Patients N (%) 14 (42.4) 14 (40.0) 0.837
Duration (hours)1 79 35 67 34 0.353
Further doses of salbutamol 17 (51.5) 23 (65.7) 0.234
Nebulized epinephrine 9 (27.3) 5 (14.3) 0.186
Systemic corticosteroids 8 (24.2) 10 (28.6) 0.686
Antibiotics 18 (54.5) 13 (37.1) 0.150
Diuretics 4 (12.1) 2 (5.7) 0.352
1Patients without oxygen, respectively tube fed, were excluded for analyses.
TABLE 5—Adverse Effects Noted in Each Group N(%)
Symptom
Hypertonic saline
Group I (HS)
N¼ 33
Normal saline
Group II (NS)
N¼ 35 P value
Sudden bronchial constriction 2 (6.1) 2 (5.7) 0.952
Apnoe 0 0
Cyanosis 0 0
Exacerbation of coughing 15 (45.5) 7 (20.0) 0.025
Excessive rhinorrhoe 19 (57.6) 11 (31.4) 0.030
Saturation dips 0 0
Tachycardia >200 cpm 0 0
Agitation 9 (27.3) 12 (34.3) 0.532
Vomiting 0 0
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One of the strengths in our study was a detailed record
of adverse effects potentially attributable to HS. It was
difficult to blame medication for symptoms that could
largely be due to acute bronchiolitis itself. Excessive
rhinorrhoe and coughingwasmore prevalent in HS group,
as recently described by Teunissen.14 We believe that
exacerbation of rhinorrhoe and cough could be explained
by physiological effects of HS and should not be
considered a negative effect. HS solutions diminish
mucosal edema, and stimulate mechanical cleansing of
secretions, increasing intrabronchiolar water andmucous,
with subsequent cough and nasal discharge. These
changes, as well as possible immune modifications
associated with sodium chloride are still not completely
understood in bronchiolitis.11–13,24,26,28,30
In conclusion, we showed that, in children younger than
12 months old that were hospitalized with acute viral
bronchiolitis, nebulized 3% HS, when compared to 0.9%
NS, although safe, did not reduce duration of hospital stay,
clinical severity score, need for supplemental oxygen, tube
feeding, or add-on medications. Our results do not support
the routine use of HS in infants with bronchiolitis.
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